1. Macarron R, Banks MN, Bojanic D, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10(3):188-195. doi: 10.1038/nrd3368

 

2. Wigglesworth MJ, Murray DC, Blackett CJ, Kossenjans M, Nissink JW. Increasing the delivery of next generation therapeutics from high throughput screening libraries. Curr Opin Chem Biol. 2015;26:104-110. doi: 10.1016/j.cbpa.2015.04.006

 

3. Pereira DA, Williams JA. Origin and evolution of high throughput screening. Br J Pharmacol. 2007;152(1):53-61. doi: 10.1038/sj.bjp.0707373

 

4. Shun TY, Lazo JS, Sharlow ER, Johnston PA. Identifying actives from HTS data sets: Practical approaches for the selection of an appropriate HTS data-processing method and quality control review. J Biomol Screen. 2011;16(1):1-14. doi: 10.1177/1087057110389039

 

5. Dreiman GHS, Bictash M, Fish PV, Griffin L, Svensson F. Changing the HTS paradigm: AI-driven iterative screening for hit finding. SLAS Discov. 2021;26(2):257-262. doi: 10.1177/2472555220949495

 

6. Tsoli M, Wadham C, Pinese M, et al. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. Cancer Biol Ther. 2018;19(12):1078-1087. doi: 10.1080/15384047.2018.1491498

 

7. Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol. 2009;9(5):580-588. doi: 10.1016/j.coph.2009.08.004

 

8. Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. Int J Mol Sci. 2012;13(1):427-452. doi: 10.3390/ijms13010427

 

9. Milinkovic A, Martínez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther. 2004;2(3):367-373. doi: 10.1586/14787210.2.3.367

 

10. FDA. Approved Drugs Generated from High Throughput Screening Efforts I -20190719. Rome: FDA; 2019.

 

11. Coussens NP, Braisted JC, Peryea T, Sittampalam GS, Simeonov A, Hall MD. Small-molecule screens: A gateway to cancer therapeutic agents with case studies of food and drug administration-approved drugs. Pharmacol Rev. 2017;69(4):479-496. doi: 10.1124/pr.117.013755

 

12. Woodward AA, Urbanowicz RJ, Naj AC, Moore JH. Genetic heterogeneity: Challenges, impacts, and methods through an associative lens. Genet Epidemiol. 2022;46(8):555-571. doi: 10.1002/gepi.22497

 

13. Lawson ARJ, Abascal F, Coorens THH, et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science. 2020;370(6512):75-82. doi: 10.1126/science.aba8347

 

14. Murphy N, Ward HA, Jenab M, et al. Heterogeneity of colorectal cancer risk factors by anatomical subsite in 10 European countries: A multinational cohort study. Clin Gastroenterol Hepatol. 2019;17(7):1323-1331.e6. doi: 10.1016/j.cgh.2018.07.030

 

15. Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79-92. doi: 10.1038/s41585-020-00400-w

 

16. Mitelpunkt A, Galili T, Kozlovski T, et al. Novel Alzheimer’s disease subtypes identified using a data and knowledge driven strategy. Sci Rep. 2020;10(1):1327. doi: 10.1038/s41598-020-57785-2

 

17. Margineanu DG. Systems biology, complexity, and the impact on antiepileptic drug discovery. Epilepsy Behav. 2014;38:131-142. doi: 10.1016/j.yebeh.2013.08.029

 

18. Kell DB. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J. 2013;280(23):5957-5980. doi: 10.1111/febs.12268

 

19. Ericson E, Gebbia M, Heisler LE, et al. Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. PLoS Genet. 2008;4(8):e1000151. doi: 10.1371/journal.pgen.1000151

 

20. Lim H, Poleksic A, Yao Y, et al. Large-scale off-target identification using fast and accurate dual regularized one-class collaborative filtering and its application to drug repurposing. PLoS Comput Biol. 2016;12(10):e1005135. doi: 10.1371/journal.pcbi.1005135

 

21. Lin A, Giuliano CJ, Palladino A, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med. 2019;11(509):eaaw8412. doi: 10.1126/scitranslmed.aaw8412

 

22. Koeberle A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today. 2014;19(12):1871-1882. doi: 10.1016/j.drudis.2014.08.006

 

23. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630-1639. doi: 10.1158/0008-5472.Can-05-1182

 

24. Flinn IW, O’Brien S, Kahl B, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 2018;131(8):877-887. doi: 10.1182/blood-2017-05-786566

 

25. Murai R, Yoshida Y, Muraguchi T, et al. A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget. 2010;1(4):252-264.

 

26. Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16(7):748-759. doi: 10.1038/s41565-021-00931-2

 

27. Ohtaka H, Velázquez-Campoy A, Xie D, Freire E. Overcoming drug resistance in HIV-1 chemotherapy: The binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 2002;11(8):1908-1916. doi: 10.1110/ps.0206402

 

28. Wei F, Wang S, Gou X. A review for cell-based screening methods in drug discovery. Biophys Rep. 2021;7(6):504-516. doi: 10.52601/bpr.2021.210042

 

29. Pathe-Neuschäfer-Rube A, Neuschäfer-Rube F, Püschel GP. Cell-based reporter release assay to determine the activity of calcium-dependent neurotoxins and neuroactive pharmaceuticals. Toxins (Basel). 2021;13(4):247. doi: 10.3390/toxins13040247

 

30. Sanookpan K, Nonpanya N, Sritularak B, Chanvorachote P. Ovalitenone inhibits the migration of lung cancer cells via the suppression of AKT/mTOR and epithelial-to-mesenchymal transition. Molecules. 2021;26(3):638. doi: 10.3390/molecules26030638

 

31. An WF, Tolliday N. Cell-based assays for high-throughput screening. Mol Biotechnol. 2010;45(2):180-186.

doi: 10.1007/s12033-010-9251-z

 

32. Takenaka T. Classical vs reverse pharmacology in drug discovery. BJU Int. 2001;88 Suppl 2:7-10; discussion 49-50. doi: 10.1111/j.1464-410x.2001.00112.x

 

33. Lage OM, Ramos MC, Calisto R, Almeida E, Vasconcelos V, Vicente F. Current screening methodologies in drug discovery for selected human diseases. Mar Drugs. 2018;16(8):279. doi: 10.3390/md16080279

 

34. Sriram K, Insel PA. G Protein-coupled receptors as targets for approved drugs: How many targets and how many drugs? Mol Pharmacol. 2018;93(4):251-258. doi: 10.1124/mol.117.111062

 

35. Kenny CH, Ding W, Kelleher K, et al. Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction. Anal Biochem. 2003;323(2):224-233. doi: 10.1016/j.ab.2003.08.033

 

36. Burns S, Travers J, Collins I, et al. Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreen™ high-throughput screen. SLAS Discov. 2006;11(7):822-827. doi: 10.1177/1087057106290992

 

37. Sudo K, Yamaji K, Kawamura K, et al. High-throughput screening of low molecular weight NS3-NS4A protease inhibitors using a fluorescence resonance energy transfer substrate. Antivir Chem Chemother. 2005;16(6):385-392. doi: 10.1177/095632020501600605

 

38. Swaney S, McCroskey M, Shinabarger D, Wang Z, Turner BA, Parker CN. Characterization of a high-throughput screening assay for inhibitors of elongation factor P and ribosomal peptidyl transferase activity. J Biomol Screen. 2006;11(7):736-742. doi: 10.1177/1087057106291634

 

39. Allen M, Reeves J, Mellor G. High throughput fluorescence polarization: A homogeneous alternative to radioligand binding for cell surface receptors. J Biomol Screen. 2000;5(2):63-69. doi: 10.1177/108705710000500202

 

40. Xu J, Wang X, Ensign B, et al. Ion-channel assay technologies: Quo vadis? Drug Discov Today. 2001;6(24):1278-1287. doi: 10.1016/s1359-6446(01)02095-5

 

41. Parker GJ, Law TL, Lenoch FJ, Bolger RE. Development of high throughput screening assays using fluorescence polarization: Nuclear receptor-ligand-binding and kinase/ phosphatase assays. J Biomol Screen. 2000;5(2):77-88. doi: 10.1177/108705710000500204

 

42. Bagal SK, Brown AD, Cox PJ, et al. Ion channels as therapeutic targets: A drug discovery perspective. J Med Chem. 2013;56(3):593-624. doi: 10.1021/jm3011433

 

43. Morachis JM, Huang R, Emerson BM. Identification of kinase inhibitors that target transcription initiation by RNA polymerase II. Oncotarget. 2011;2(1-2):18-28. doi: 10.18632/oncotarget.212

 

44. Blay V, Tolani B, Ho SP, Arkin MR. High-throughput screening: Today’s biochemical and cell-based approaches. Drug Discov Today. 2020;25(10):1807-1821. doi: 10.1016/j.drudis.2020.07.024

 

45. Glickman JF. Assay development for protein kinase enzymes. In: Markossian S, Grossman A, Brimacombe K, et al, editors. Assay Guidance Manual. United States: Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.

 

46. Harner MJ, Frank AO, Fesik SW. Fragment-based drug discovery using NMR spectroscopy. J Biomol NMR. 2013;56(2):65-75. doi: 10.1007/s10858-013-9740-z

 

47. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-599. doi: 10.1038/nature09454

 

48. Jadhav GP, Prathipati PK, Chauhan H. Surface plasmon resonance, Orbitrap mass spectrometry and Raman advancements: Exciting new techniques in drug discovery. Expert Opin Drug Discov. 2020;15(7):739-743. doi: 10.1080/17460441.2020.1745771

 

49. Imaduwage KP, Lakbub J, Go EP, Desaire H. Rapid LC-MS based high-throughput screening method, affording no false positives or false negatives, identifies a new inhibitor for carbonic anhydrase. Sci Rep. 2017;7(1):10324. doi: 10.1038/s41598-017-08602-w

 

50. McLaren DG, Shah V, Wisniewski T, et al. High-throughput mass spectrometry for hit identification: Current landscape and future perspectives. SLAS Discov. 2021;26(2):168-191. doi: 10.1177/2472555220980696

 

51. Lu Y, Qin S, Zhang B, et al. Accelerating the throughput of affinity mass spectrometry-based ligand screening toward a G protein-coupled receptor. Anal Chem. 2019;91(13):8162-8169. doi: 10.1021/acs.analchem.9b00477

 

52. Gilbert IH. Drug discovery for neglected diseases: Molecular target-based and phenotypic approaches. J Med Chem. 2013;56(20):7719-7726. doi: 10.1021/jm400362b

 

53. Chen GQ, Xu Y, Shen SM, Zhang J. Phenotype and target-based chemical biology investigations in cancers. Natl Sci Rev. 2019;6(6):1111-1127. doi: 10.1093/nsr/nwy124

 

54. Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.

doi: 10.1155/2014/357027

 

55. Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy. J Hematol Oncol. 2018;11(1):84. doi: 10.1186/s13045-018-0624-2

 

56. Dong B, Liang Z, Chen Z, et al. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation. Sci China Life Sci. 2018;61(9):999-1009. doi: 10.1007/s11427-018-9324-y

 

57. Liu C, Nie D, Li J, et al. Antitumor effects of blocking protein neddylation in T315I-BCR-ABL leukemia cells and leukemia stem cells. Cancer Res. 2018;78(6):1522-1536. doi: 10.1158/0008-5472.Can-17-1733

 

58. Misra S, Zhang X, Wani NA, Sizemore S, Ray A. Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment. Oncotarget. 2020;11(8):784-800. doi: 10.18632/oncotarget.27485

 

59. Swinney DC, Lee JA. Recent advances in phenotypic drug discovery. F1000Res. 2020;9:F1000. doi: 10.12688/f1000research.25813.1

 

60. McKinney JD, Richard A, Waller C, Newman MC, Gerberick F. The practice of structure activity relationships (SAR) in toxicology. Toxicol Sci. 2000;56(1):8-17. doi: 10.1093/toxsci/56.1.8

 

61. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi: 10.1021/acs.jnatprod.9b01285

 

62. Krejci P, Pejchalova K, Wilcox WR. Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway. Invest New Drugs. 2007;25(4):391-395. doi: 10.1007/s10637-007-9054-7

 

63. Chambers C, Smith F, Williams C, et al. Measuring intracellular calcium fluxes in high throughput mode. Comb Chem High Throughput Screen. 2003;6(4):355-362. doi: 10.2174/138620703106298446

 

64. Kariv I, Stevens ME, Behrens DL, Oldenburg KR. High throughput quantitation of cAMP production mediated by activation of seven transmembrane domain receptors. J Biomol Screen. 1999;4(1):27-32. doi: 10.1177/108705719900400105

 

65. Eggert US, Kiger AA, Richter C, et al. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol. 2004;2(12):e379.

doi: 10.1371/journal.pbio.0020379

 

66. Beck V, Pfitscher A, Jungbauer A. GFP-reporter for a high throughput assay to monitor estrogenic compounds. J Biochem Biophys Methods. 2005;64(1):19-37. doi: 10.1016/j.jbbm.2005.05.001

 

67. Yarrow JC, Totsukawa G, Charras GT, Mitchison TJ. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem Biol. 2005;12(3):385-395. doi: 10.1016/j.chembiol.2005.01.015

 

68. Vincent F, Loria P, Pregel M, et al. Developing predictive assays: The phenotypic screening “rule of 3”. Sci Transl Med. 2015;7(293):293ps15. doi: 10.1126/scitranslmed.aab1201

 

69. Engle SJ, Vincent F. Small molecule screening in human induced pluripotent stem cell-derived terminal cell types. J Biol Chem. 2014;289(8):4562-4570. doi: 10.1074/jbc.R113.529156

 

70. McNeish J, Roach M, Hambor J, et al. High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of α-amino-3-hydroxyl-5-methyl-4- isoxazolepropionate-type glutamate receptors. J Biol Chem. 2010;285(22):17209-17217. doi: 10.1074/jbc.M109.098814

 

71. Ashlock MA, Olson ER. Therapeutics development for cystic fibrosis: A successful model for a multisystem genetic disease. Annu Rev Med. 2011;62:107-125. doi: 10.1146/annurev-med-061509-131034

 

72. Van Goor F, Hadida S, Grootenhuis PDJ, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011;108(46):18843-18848. doi: 10.1073/pnas.1105787108

 

73. Lee G, Ramirez CN, Kim H, et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol. 2012;30(12):1244-1248. doi: 10.1038/nbt.2435

 

74. Barberis A, Gunde T, Berset C, Audetat S, Lüthi U. Yeast as a screening tool. Drug Discov Today Technol. 2005;2(2):187-192. doi: 10.1016/j.ddtec.2005.05.022

 

75. Balgi AD, Roberge M. Screening for chemical inhibitors of heterologous proteins expressed in yeast using a simple growth-restoration assay. Methods Mol Biol. 2009;486:125-137. doi: 10.1007/978-1-60327-545-3_9

 

76. Puri AW, Bogyo M. Using small molecules to dissect mechanisms of microbial pathogenesis. ACS Chem Biol. 2009;4(8):603-616. doi: 10.1021/cb9001409

 

77. Zlitni S, Blanchard JE, Brown ED. High-throughput screening of model bacteria. Methods Mol Biol. 2009;486:13-27.

 

78. Hong CC. Large-scale small-molecule screen using zebrafish embryos. Methods Mol Biol. 2009;486:43-55. doi: 10.1007/978-1-60327-545-3_4

 

79. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov. 2005;4(1):35-44. doi: 10.1038/nrd1606

 

80. O’Rourke EJ, Conery AL, Moy TI. Whole-animal high-throughput screens: The C. elegans model. Methods Mol Biol. 2009;486:57-75. doi: 10.1007/978-1-60327-545-3_5

 

81. Agee A, Carter D. Whole-organism screening: Plants. Methods Mol Biol. 2009;486:77-95. doi: 10.1007/978-1-60327-545-3_6

 

82. Norambuena L, Raikhel NV, Hicks GR. Chemical genomics approaches in plant biology. Plant Syst Biol. 2009;553:345-354. doi: 10.1007/978-1-60327-563-7_18

 

83. Stern HM, Murphey RD, Shepard JL, et al. Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat Chem Biol. 2005;1(7):366-370. doi: 10.1038/nchembio749

 

84. Hong CC, Peterson QP, Hong JY, Peterson RT. Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling. Curr Biol. 2006;16(13):1366-1372. doi: 10.1016/j.cub.2006.05.046

 

85. Swinney DC. The value of translational biomarkers to phenotypic assays. Front Pharmacol. 2014;5:171. doi: 10.3389/fphar.2014.00171

 

86. Ioannidis JP. Biomarker failures. Clin Chem. 2013;59(1):202-204. doi: 10.1373/clinchem.2012.185801

 

87. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res. 2008;14(19):5967-5976. doi: 10.1158/1078-0432.Ccr-07-4535

 

88. Spreafico R, Soriaga LB, Grosse J, Virgin HW, Telenti A. Advances in genomics for drug development. Genes (Basel). 2020;11(8):942. doi:10.3390/genes11080942

 

89. Guo JB, Li XJ. Impacts of modern biology on drug discovery. Sheng Li Ke Xue Jin Zhan. 2007;38(1):25-31.

 

90. Hong AL, Tseng YY, Cowley GS, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016;7:11987. doi: 10.1038/ncomms11987

 

91. Lin X, Huang XP, Chen G, et al. Life beyond kinases: Structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. J Med Chem. 2012;55(12):5749-5759. doi: 10.1021/jm300338m

 

92. Schneidewind T, Brause A, Pahl A, et al. Morphological profiling identifies a common mode of action for small molecules with different targets. Chembiochem. 2020;21(22):3197-3207. doi: 10.1002/cbic.202000381

 

93. Han X, Zhou C, Jiang M, et al. Discovery of RG7834: The first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action. J Med Chem. 2018;61(23):10619-10634. doi: 10.1021/acs.jmedchem.8b01245

 

94. Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. Opportunities and challenges in phenotypic drug discovery: An industry perspective. Nat Rev Drug Discov. 2017;16(8):531-543. doi: 10.1038/nrd.2017.111

 

95. Vincent F, Loria PM, Weston AD, et al. Hit triage and validation in phenotypic screening: Considerations and strategies. Cell Chem Biol. 2020;27(11):1332-1346. doi: 10.1016/j.chembiol.2020.08.009

 

96. Warchal SJ, Unciti-Broceta A, Carragher NO. Next-generation phenotypic screening. Future Med Chem. 2016;8(11):1331-1347. doi: 10.4155/fmc-2016-0025

 

97. Comess KM, McLoughlin SM, Oyer JA, et al. Emerging approaches for the identification of protein targets of small molecules-a practitioners’ perspective. J Med Chem. 2018;61(19):8504-8535. doi: 10.1021/acs.jmedchem.7b01921

 

98. Lee J, Bogyo M. Target deconvolution techniques in modern phenotypic profiling. Curr Opin Chem Biol. 2013;17(1):118-126. doi: 10.1016/j.cbpa.2012.12.022

 

99. Lu JJ, Pan W, Hu YJ, Wang YT. Multi-target drugs: the trend of drug research and development. PLoS One. 2012;7(6):e40262. doi: 10.1371/journal.pone.0040262

 

100. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z

 

101. Keller MP, Attie AD. Physiological insights gained from gene expression analysis in obesity and diabetes. Annu Rev Nutr. 2010;30:341-364. doi: 10.1146/annurev.nutr.012809.104747

 

102. Van’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452(7187):564-570. doi: 10.1038/nature06915

 

103. Bertos NR, Park M. Breast cancer-one term, many entities? J Clin Invest. 2011;121(10):3789-3796.

doi: 10.1172/JCI57100

 

104. Huang E, Ishida S, Pittman J, et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet. 2003;34(2):226-230. doi: 10.1038/ng1167

 

105. Loboda A, Nebozhyn M, Klinghoffer R, et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics. 2010;3(1):26. doi: 10.1186/1755-8794-3-26

 

106. Loboda A, Nebozhyn MV, Watters JW, et al. EMT is the dominant program in human colon cancer. BMC Med Genomics. 2011;4(1):9. doi: 10.1186/1755-8794-4-9

 

107. Méndez-Lucio O, Naveja JJ, Vite-Caritino H, Prieto-Martínez FD, Medina-Franco JL. One drug for multiple targets: A computational perspective. J Mex Chem Soc. 2016;60(3):168-181. doi: 10.29356/jmcs.v60i3.100

 

108. Hsieh JH, Smith-Roe SL, Huang R, et al. Identifying compounds with genotoxicity potential using Tox21 high-throughput screening assays. Chem Res Toxicol. 2019;32(7):1384-1401. doi: 10.1021/acs.chemrestox.9b00053

 

109. Michod D, Widmann C. DNA-damage sensitizers: Potential new therapeutical tools to improve chemotherapy. Crit Rev Oncol Hematol. 2007;63(2):160-171. doi: 10.1016/j.critrevonc.2007.04.003

 

110. Evans TJ, Yamamoto KN, Hirota K, Takeda S. Mutant cells defective in DNA repair pathways provide a sensitive high-throughput assay for genotoxicity. DNA Repair (Amst). 2010;9(12):1292-1298. doi: 10.1016/j.dnarep.2010.09.017

 

111. Ji K, Kogame T, Choi K, et al. A novel approach using DNA-repair-deficient chicken DT40 cell lines for screening and characterizing the genotoxicity of environmental contaminants. Environ Health Perspect. 2009;117(11):1737-1744. doi: 10.1289/ehp.0900842

 

112. Buerstedde JM, Takeda S. Increased ratio of targeted torandom integration after transfection of chicken B cell lines. Cell. 1991;67(1):179-188. doi: 10.1016/0092-8674(91)90581-i

 

113. Yamazoe M, Sonoda E, Hochegger H, Takeda S. Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40. DNA Repair (Amst). 2004;3(8-9):1175-1185. doi: 10.1016/j.dnarep.2004.03.039

 

114. Walmsley RM, Tate M. The GADD45a-GFP greenscreen HC assay. Methods Mol Biol. 2012;817:231-250. doi: 10.1007/978-1-61779-421-6_12

 

115. Knight AW, Little S, Houck K, et al. Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast™ chemicals. Regul Toxicol Pharmacol. 2009;55(2):188-199. doi: 10.1016/j.yrtph.2009.07.004

 

116. Hastwell PW, Chai LL, Roberts KJ, et al. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat Res. 2006;607(2):160-175. doi: 10.1016/j.mrgentox.2006.04.011

 

117. Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Johnston PA. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen. 2010;15(7):783-797. doi: 10.1177/1087057110376413

 

118. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 1981;41(5):1751-1756.

 

119. Xing JZ, Zhu L, Gabos S, Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol In Vitro. 2006;20(6):995-1004. doi: 10.1016/j.tiv.2005.12.008

 

120. Fox JT, Sakamuru S, Huang R, et al. High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death. Proc Natl Acad Sci. 2012;109(14):5423-5428. doi: 10.1073/pnas.1114278109

 

121. Sikdar N, Banerjee S, Lee KY, et al. DNA damage responses by human ELG1 in S phase are important to maintain genomic integrity. Cell Cycle. 2009;8(19):3199-3207. doi: 10.4161/cc.8.19.9752

 

122. Scholes DT, Banerjee M, Bowen B, Curcio MJ. Multiple regulators of Ty1 transposition in Saccharomyces cerevisiae have conserved roles in genome maintenance. Genetics. 2001;159(4):1449-1465. doi: 10.1093/genetics/159.4.1449

 

123. Sykora P, Witt KL, Revanna P, et al. Next generation high throughput DNA damage detection platform for genotoxic compound screening. Sci Rep. 2018;8(1):2771. doi: 10.1038/s41598-018-20995-w

 

124. Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005;111:127-148.

doi: 10.1385/1-59259-889-7:127

 

125. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58. doi: 10.1038/nrc706

 

126. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett. 2006;580(4):998-1009. doi: 10.1016/j.febslet.2005.12.060

 

127. Sharom FJ. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105-127. doi: 10.2217/14622416.9.1.105

 

128. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94(5):2031-2035. doi: 10.1073/pnas.94.5.2031

 

129. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221(4617):1285-1288. doi: 10.1126/science.6137059

 

130. Shen DW, Cardarelli C, Hwang J, et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem. 1986;261(17):7762-7770.

 

131. Roe M, Folkes A, Ashworth P, et al. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett. 1999;9(4):595-600. doi: 10.1016/s0960-894x(99)00030-x

 

132. Dantzig AH, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999;290(2):854-862.

 

133. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001;61(2):749-758.

 

134. Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: Lessons from clinical oncology. Novartis Found Symp. 2002;243:83-96; discussion 96-102, 180-185.

 

135. Dalton W. Detection of multidrug resistance gene expression in multiple myeloma. Leukemia. 1997;11(7):1166-1169. doi: 10.1038/sj.leu.2400724

 

136. Susa M, Choy E, Yang C, et al. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay. J Biomol Screen. 2010;15(3):287-296. doi: 10.1177/1087057109359422

 

137. Winter SS, Lovato DM, Khawaja HM, et al. High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent. J Biomol Screen. 2008;13(3):185-193. doi: 10.1177/1087057108314610

 

138. Duan Z, Choy E, Hornicek FJ. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One. 2009;4(10):e7415. doi: 10.1371/journal.pone.0007415

 

139. Ivnitski-Steele I, Larson RS, Lovato DM, et al. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol. 2008;6(2):263-276. doi: 10.1089/adt.2007.107

 

140. Gurdon JB, Elsdale TR, Fischberg M. Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature. 1958;182(4627):64-65. doi: 10.1038/182064a0

 

141. Hass R, von der Ohe J, Ungefroren H. The intimate relationship among EMT, MET and TME: AT (ransdifferentiation) E (nhancing) M (ix) to be exploited for therapeutic purposes. Cancers. 2020;12(12):3674. doi: 10.3390/cancers12123674

 

142. Saito S, Lin YC, Nakamura Y, et al. Potential application of cell reprogramming techniques for cancer research. Cell Mol Life Sci. 2019;76:45-65. doi: 10.1007/s00018-018-2924-7

 

143. Welch DR. Tumor heterogeneity-a “contemporary concept” founded on historical insights and predictions. Cancer Res. 2016;76(1):4-6. doi: 10.1158/0008-5472.CAN-15-3024

 

144. Denny SK, Yang D, Chuang CH, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell. 2016;166(2):328-342. doi: 10.1016/j.cell.2016.05.052

 

145. Teng S, Li YE, Yang M, et al. Tissue-specific transcription reprogramming promotes liver metastasis of colorectal cancer. Cell Res. 2020;30(1):34-49. doi: 10.1038/s41422-019-0259-z

 

146. Van Keymeulen A, Lee MY, Ousset M, et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature. 2015;525(7567):119-123. doi: 10.1038/nature14665

 

147. Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017;51(5):1357-1369. doi: 10.3892/ijo.2017.4129

 

148. Zheng YW, Nie YZ, Taniguchi H. Cellular reprogramming and hepatocellular carcinoma development. World J Gastroenterol. 2013;19(47):8850-8860. doi: 10.3748/wjg.v19.i47.8850

 

149. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21(2):163-167. doi: 10.1038/5947

 

150. Wang D, Garcia-Bassets I, Benner C, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474(7351):390-394. doi: 10.1038/nature10006

 

151. Li HF, Keeton A, Vitolo M, et al. A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells. J Biomol Screen. 2011;16(4):383-393. doi: 10.1177/1087057110397357

 

152. Qin L, Yin YT, Zheng FJ, et al. WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis. Oncotarget. 2015;6(12):10239-10252. doi: 10.18632/oncotarget.3518

 

153. Ewan K, Pajak B, Stubbs M, et al. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res. 2010;70(14):5963-5973. doi: 10.1158/0008-5472.Can-10-1028

 

154. Bialkowska AB, Yang VW. High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer. Future Oncol. 2012;8(3):259-272. doi: 10.2217/fon.12.19

 

155. Lepourcelet M, Chen YNP, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell. 2004;5(1):91-102. doi: 10.1016/S1535-6108(03)00334-9

 

156. Yu W, Ma Y, Shankar S, Srivastava RK. SATB2/β-catenin/ TCF-LEF pathway induces cellular transformation by generating cancer stem cells in colorectal cancer. Sci Rep. 2017;7(1):10939. doi: 10.1038/s41598-017-05458-y

 

157. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol. 2001;19(10):940-945. doi: 10.1038/nbt1001-940
158. Mallon R, Feldberg L, Kim S, et al. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. Mol Cancer Ther. 2004;3(6):755-762.

 

159. Rissmann R, Hessel MH, Cohen AF. Vemurafenib/ dabrafenib and trametinib. Br J Clin Pharmacol. 2015;80(4):765-767. doi: 10.1111/bcp.12651

 

160. Fu H, Gao H, Qi X, et al. Aldolase A promotes proliferation and G 1/S transition via the EGFR/MAPK pathway in non-small cell lung cancer. Cancer Commun (Lond). 2018;38:18. doi: 10.1186/s40880-018-0290-3

 

161. Champer M, Miller D, Kuo DYS. Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report. Gynecol Oncol Rep. 2019;28:26-28. doi: 10.1016/j.gore.2019.01.007

 

162. Liu S, Zou Q, Chen JP, et al. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. J Clin Invest. 2021;131(20):e145035. doi: 10.1172/jci145035

 

163. Yuliantie E, Dai X, Yang D, Crack PJ, Wang MW. High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway. Acta Pharm Sin B. 2018;8(6):889-899. doi: 10.1016/j.apsb.2018.07.005

 

164. Dillon KJ, Smith GC, Martin NM. A FlashPlate assay for the identification of PARP-1 inhibitors. J Biomol Screen. 2003;8(3):347-352. doi: 10.1177/1087057103008003013

 

165. Bapat A, Glass LS, Luo M, et al. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther. 2010;334(3):988-998. doi: 10.1124/jpet.110.169128

 

166. Peterson EJ, Janzen WP, Kireev D, Singleton SF. High-throughput screening for RecA inhibitors using a transcreener adenosine 5’-O-diphosphate assay. Assay Drug Dev Technol. 2012;10(3):260-268. doi: 10.1089/adt.2011.0409

 

167. Sexton JZ, Wigle TJ, He Q, et al. Novel inhibitors of E. coli RecA ATPase activity. Curr Chem Genomics. 2010;4:34-42. doi: 10.2174/1875397301004010034

 

168. Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol. 2011;6(6):628-635. doi: 10.1021/cb100428c

 

169. Huang L, Yi X, Yu X, et al. High-throughput strategies for the discovery of anticancer drugs by targeting transcriptional reprogramming. Front Oncol. 2021;11:762023. doi: 10.3389/fonc.2021.762023

 

170. Shaw J, Dale I, Hemsley P, et al. Positioning high-throughput CETSA in early drug discovery through screening against B-Raf and PARP1. SLAS Discov. 2019;24(2):121-132. doi: 10.1177/2472555218813332

 

171. Howard RT, Hemsley P, Petteruti P, et al. Structure-guided design and in-cell target profiling of a cell-active target engagement probe for PARP inhibitors. ACS Chem Biol. 2020;15(2):325-333. doi: 10.1021/acschembio.9b00963

 

172. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068. doi: 10.1038/nature07385

 

173. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069-1075. doi: 10.1038/nature07423

 

174. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-1806. doi: 10.1126/science.1164368

 

175. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer Res Treat. 1998;52(1-3):17-28. doi: 10.1023/a:1006102916060

 

176. Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer. 2001;92(3):370-373. doi: 10.1002/ijc.1200

 

177. Dhillon NK, Mudryj M. Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells. Genes Immun. 2003;4(5):336-342. doi: 10.1038/sj.gene.6363973

 

178. Niu D, Wang G, Wang X. Up-regulation of cyclin E in breast cancer via estrogen receptor pathway. Int J Clin Exp Med. 2015;8(1):910-915.

 

179. Warner SL, Munoz RM, Stafford P, et al. Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther. 2006;5(10):2450-2458. doi: 10.1158/1535-7163.Mct-06-0202

 

180. Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A. 2006;103(29):11003-11008. doi: 10.1073/pnas.0604507103

 

181. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther. 2002;2(1):3-24. doi: 10.1517/14712598.2.1.3

 

182. Magwenyane AM, Ugbaja SC, Amoako DG, Somboro AM, Khan RB, Kumalo HM. Heat shock protein 90 (HSP90) inhibitors as anticancer medicines: A review on the computer-aided drug discovery approaches over the past five years. Comput Math Methods Med. 2022;2022:2147763. doi: 10.1155/2022/2147763

 

183. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93(4):309-314. doi: 10.1093/jnci/93.4.309

 

184. Semenza GL. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 2002;8(4 Suppl):S62-S67. doi: 10.1016/s1471-4914(02)02317-1

 

185. Masoud GN, Li W. HIF-1α pathway: Role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378-389. doi: 10.1016/j.apsb.2015.05.007

 

186. Workman P. Scoring a bull’s-eye against cancer genome targets. Curr Opin Pharmacol. 2001;1(4):342-352. doi: 10.1016/s1471-4892(01)00060-1

 

187. Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med. 2000;6(8):623-644.

 

188. Turlais F, Hardcastle A, Rowlands M, et al. High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate). Anal Biochem. 2001;298(1):62-68. doi: 10.1006/abio.2001.5340

 

189. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today. 2009;14(19-20):942-948. doi: 10.1016/j.drudis.2009.06.008

 

190. Miles DW. Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting. Breast Cancer Res. 2001;3(6):380-384. doi: 10.1186/bcr326

 

191. Kelland LR, Smith V, Valenti M, et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res. 2001;7(11):3544-3550.

 

192. Johnston SR. Farnesyl transferase inhibitors: A novel targeted tnerapy for cancer. Lancet Oncol. 2001;2(1):18-26. doi: 10.1016/s1470-2045(00)00191-1

 

193. Nicholls H. Aromatase inhibitors continue their ATAC on tamoxifen. Trends Mol Med. 2002;8(4 Suppl):S12-S13. doi: 10.1016/s1471-4914(02)02304-3

 

194. Buzdar AU. Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting? Br J Cancer. 2001;85 Suppl 2(Suppl 2):6-10. doi: 10.1054/bjoc.2001.1983

 

195. Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5(2):100-107. doi: 10.1038/nchembio.137

 

196. Zhang N, Wu B, Powell D, et al. Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino) quinolines as MEK (MAPKK) inhibitors. Bioorg Med Chem Lett. 2000;10(24):2825-2828. doi: 10.1016/S0960-894X(00)00580-1

 

197. Berger D, Dutia M, Powell D, et al. Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorg Med Chem Lett. 2003;13(18):3031-3034. doi: 10.1016/s0960-894x(03)00640-1

 

198. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994;265(5175):1093-1095. doi: 10.1126/science.8066447